Effectiveness, safety and drug survival of dupilumab in patients with moderate to severe atopic dermatitis: an interim analysis of the TREATgermany registry

Stoelzl D, Boraczynski N, Heratizadeh A, Haufe E, Harder I, Abraham S, Heinrich L, Kleinheinz A, Wollenberg A, Weisshaar E, Schaekel K, Ertner K, Wiemers F, Wildberger J, Worm M, Von Kiedrowski R, Effendy I, Asmussen A, Augustin M, Pawlak M, Sticherling M, Zink A, Hilgers M, Handrick C, Quist S, Schwarz B, Staubach-Renz P, Bell M, Hong-Weldemann S, Homey B, Bruecher J, Schmitt J, Werfel T, Weidinger S (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: E39-E40

Conference Proceedings Title: EXPERIMENTAL DERMATOLOGY

Authors with CRIS profile

Involved external institutions

Technische Universität Dresden Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Heinrich-Heine-Universität Düsseldorf Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Co-med GmbH & Co.KG Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Klinikum Bielefeld Rosenhöhe Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Ludwig-Maximilians-Universität (LMU) Germany (DE) Elbe Kliniken Stade-Buxtehude Germany (DE) Technische Universität München (TUM) Germany (DE)

How to cite

APA:

Stoelzl, D., Boraczynski, N., Heratizadeh, A., Haufe, E., Harder, I., Abraham, S.,... Weidinger, S. (2022). Effectiveness, safety and drug survival of dupilumab in patients with moderate to severe atopic dermatitis: an interim analysis of the TREATgermany registry. In EXPERIMENTAL DERMATOLOGY (pp. E39-E40). HOBOKEN: WILEY.

MLA:

Stoelzl, D., et al. "Effectiveness, safety and drug survival of dupilumab in patients with moderate to severe atopic dermatitis: an interim analysis of the TREATgermany registry." Proceedings of the EXPERIMENTAL DERMATOLOGY HOBOKEN: WILEY, 2022. E39-E40.

BibTeX: Download